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We studied binding of ~zSi.labelled truncated-glucagon-like peptide-1 (proglucagon 78-107 amide) to a cloned rat insulin- 
producing cell line, RIN 5AH, in monolayer culture. Interaction of the peptide with pancreatic nsulinoma cells was satur- 
able and time dependent. Half-maximal binding was obtained when the cells were incubated in the presence of 3.3 x 10 -9 
mol/l unlabelled truncated-glucagon-like peptide-I (proglucagon 78-107 amide). Neither glucagon, full-length glucagon- 
like peptide-1 (proglucagon 72-107 amide) nor gastric inhibitory peptide competed for binding in concentrations up to 
I0 -6 mol/l. 
Proglucagon; Enteroglucagon; I cretin; Insulinotropin 
1. INTRODUCTION 
Only one mRNA codes for proglucagon, the 160 
amino acid precursor of glucagon [1,2]. The 
precursor, however, is processed ifferently in the 
pancreas, where the products are a glicentin- 
related pancreatic peptide (proglucagon 1-30), 
glucagon itself (proglucagon 33-61) and a large 
peptide, containing 2glucagon-like sequences, and 
in the small intestine, where the precursor gives rise 
to glicentin (proglucagon 1-69) and two smaller 
peptides, glucagon-like peptide-1 and glucagon- 
like peptide-2 (GLP-1 and GLP-2) (fig.l). We 
recently isolated the natural glucagon-like pep- 
tide-1 from pig ileal mucosa and found that the 
peptide corresponded to proglucagon 78-107, or 
possibly 78-108 [3]. This peptide was designated 
truncated-GLP-1. Synthetic truncated-GLP-1 has 
a strong insulinotrophic effect on the isolated pan- 
creas of pig [3] and rat [4]. A similar effect on the 
pancreas could not be obtained when identical ex- 
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periments were carried out with synthetic full- 
length GLP-1 (proglucagon 72-107 amide), ori- 
ginally believed to be a naturally occurring pro- 
glucagon product because of its flanking basic 
dipeptides in proglucagon. In this study we in- 
vestigated the binding of 125I-labelled truncated- 
GLP-1 to cells of a cloned rat insulin-producing 
cell line, RIN 5AH, in monolayer culture, to 
demonstrate he possible presence of receptors for 
this peptide on rat insulinoma cells. We also in- 
vestigated the interaction of the receptor with 
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Fig.1. Diagrammatic representation of the structure of 
proglucagon. Proglucagon (160 amino acids) consists of 
glicentin-related pancreatic poptide (GRPP), corresponding to
proglucagon 1-30, the glucagon sequence (proglucagon 
33-61), and a sequence containing 2 glucagon-like sequences; 
glucagon-like peptide-1 (GLP-1) and glucagon-like-peptide-2 
(GLP-2) (proglucagon 72-160). The structure of the naturally 
occurring peptide truncated-GLP-! (proglucagon 78-107 
amide) is indicated below (T-GLP-I). 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/88/$3.50 © 1988 Federation of European Biochemical Societies 175 
Volume 229, number 1 FEBS LETTERS February 1988 
glucagon, full-length GLP-1 and gastric inhibitory 
peptide. 
2. MATERIALS AND METHODS 
2.1. Peptides 
Both synthetic GLP-1 amide (code 7166, Peninsula, 
Merseyside, England) and synthetic truncated-GLP-1 amide ob- 
tained from Peninsula Laboratories, San Carlos, CA, by 
custom synthesis (lot no.008802) were gifts from Professor J. 
Hoist (the Panum Institute, Copenhagen, Denmark). Peptide 
purity of synthetic truncated-GLP-1 was 72%. The peptide was 
further purified by isocratic high-pressure liquid 
chromatography in 44% ethanol (Merck, Darmstadt), contain- 
ing in addition 0.1% trifluoroacetic acid (TFA; Pierce, 
Rockford, IL). Sequence determination confirmed that the pep- 
tide was proglucagon 78-107 amide. Highly purified porcine 
glucagon was obtained from the Novo Research Institute 
(Bagsv~rd, Denmark). Synthetic porcine gastric inhibitory pep- 
tide (GIP) (code 7192, Peninsula) was a gift from H. Kofod 
(Hagedorn Research Laboratory). Labelled peptides: ~25I- 
labelled, monoiodinated, biologically active glucagon was from 
the Novo Research Institute. The specific activity of ~25I- 
labelled glucagon was 34 MBq/nmoi. 125I-labelled truncated- 
GLP-I was prepared by the stoichiometric hloramine-T 
method as described [5] and purified by gel filtration on a 
Sephadex G 50, fine grade, column (Pharmacia, Uppsala, 
Sweden) in 0.04 M phosphate buffer, pH 7.4, containing in ad- 
dition 0.1% human serum albumin (reinst, trocken, Behr- 
ingwerke, Marburg, FRG) and immediately thereafter further 
purified on Sep-Pak R, C-18 cartridges (Waters Associates, 
Milford, MA) eluted with a 0-100% gradient of ethanol in 
water, containing in addition 1% TFA. The Sep-Pak R car- 
tridges were activated according to the manufacturer's ecom- 
mendations. The specific activity of 125I-labelled trun- 
cated-GLP-I was 35 MBq/nmol. 
2.2. Other materials 
RPMI 1640 and fetal calf serum were provided by Flow 
Laboratories (Irvine, Scotland). Penicillin, streptomycin and 
trypsin were obtained from Gibco (Paisley, Scotland). Human 
serum albumin was from Behringwerke, Haemaccel R from 
Behring, Marburg, and aprotinin (Trasylol R) from Bayer, 
Leverkusen. Cell culture flasks were from Nunc (Roskilde, 
Denmark) and incubation vials from BN plast (Copenhagen, 
Denmark). 
2.3. Cell line 
The RIN=SAH cell line was established from a serially 
transplantalfl¢~ radiation-induced rat islet cell tumor [6]. The 
cells wer~ grown in RPMI 1640 medium containing in addition 
10% heat-inactivated fetal calf serum (FCS), 100U/ml 
penicillin and 100~g/ml streptomycin. The flasks were in- 
cubated at 37°C in a humidified atmosphere containing 5% car- 
bon dioxide. Culture medium was changed three times a week. 
2.4. Receptor assay 
The day before the assay, cells were trypsinized (as described 
in [7]) and placed in a spinner culture flask with RPMI 1640, 
containing in addition 10 mM Hepes and 1%0 FCS at 37°C for 
16 h to allow recovery of cell membrane proteins. After spinner 
culture, the cells were centrifuged for 5 rain at 50 x g and then 
counted and tested for viability. After washing in 10 mM Hepes 
buffer, pH 7.4, containing 130 mM NaC1, 4.7 mM KCI, 
2.5 mM CaCI2, 1.4 mM MgSO4, 2.5 mM NaH2PO4, 2 g/l 
human serum albumin, haemaccel R and 800000 KIU 
aprotinin/l, the cell suspension was diluted to contain approx. 
2.5 x 106 cells per 800/A. 800/zl cell suspension, 100/zl 125I- 
labelled truncated-GLP-I (approx. 50000 cpm) and 100/zl sam- 
ple or buffer were placed in a 25 ml scintillation vial. The vials 
were incubated in a shaking water bath at either 4°C or 20°C 
for various periods of time. Two samples of 400/A were then 
placed in 550/A microfuge tubes containing 100/A dibutyl 
phthalate and centrifuged for 1 rain at 10000 x g. The tips of 
the tubes were cut through the oil phase and counted in a gam- 
ma counter. 
2.5. Calculations 
The specific binding was determined by subtraction from 
total cell-associated radioactivity, the radioactivity obtained in 
the presence of a surplus of uniabelled truncated-GLP-I (6 x 
10 -7 mol/1). The latter, the non-specific binding (NSB), was 
64% ( + 3) in 10 experiments of the binding of the labelled pep- 
tide alone. In 10 experiments he binding of the labelled peptide 
alone was 3.0 + 0.4% (_+ SE) of the total added radioactivity. 
All incubations were made in duplicate and the mean values 
used for further calculations. The mean percent binding ± SE 
at each hormone concentration was calculated and plotted 
against he dose on a semilogarithmic s ale. 
3. RESULTS 
The  t ime course  o f  to ta l  ~25I-labelled t runcated-  
GLP-1  b ind ing  and  non-spec i f i c  b ind ing  to  
R IN-SAH cells was s tud ied  at  20°C and  4°C .  A t  
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Fig.2. Displacement of binding of 125I-labelled truncated- 
GLP-1 with unlabelled truncated-GLP-l in RIN 5AH cells (n = 
10). The mean binding of ~25I-labelled truncated-GLP-I + SE 
as %0 of control (= no addition of unlabelled peptide) is plotted 
against he concentrations of unlabelled peptide added. 
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the ~25I-labelled truncated-GLP-1 concentration 
used (approx. 0.1 pmol) the total binding at 20°C 
increased with time. A plateau was reached at 
30 min. At 4°C, the binding increased for 4 h. The 
non-specific binding at the two different 
temperatures did not differ. The degradation of 
~25I-labelled truncated-GLP-1 during incubation 
was tested by precipitation with 5% (final concen- 
tration) trichloroacetic acid of a sample of the 
supernatant from the incubation mixture after a 
4 h incubation at 4°C. Compared to nonincubated 
labelled peptide, of which 94.7 + 2% (mean + SE 
of  4 experiments) of the radioactivity was 
precipitable in 5% trichloroacetic acid, 81.8 _+ 
1.5% (mean + SE of 4 experiments) of the radioac- 
tivity was precipitable. The binding of t25I-labelled 
truncated-GLP-1 was displaced by unlabelled 
truncated-GLP-1, and 50% displacement was ob- 
tained in the presence of 3.3 + 0.3 x 10 -9 mol/1 
(fig.2). Neither glucagon (10 -6 mol/l), GLP-1 (6 × 
10 -7 mol/l) nor gastric inhibitory peptide (3 x 
10 -7  mol/l) were able to displace the binding of 
125I-labelled truncated-GLP-1 in five consecutive 
experiments (fig,3). 
The binding of 125I-glucagon was displaced by 
glucagon. 50% displacement was obtained in the 
presence of 2.9 x 10 -9 mol/1 (not shown). 
Truncated-GLP-1, 6 x 10-7mol/ l ,  did not 
displace the binding of 125I-labelled glucagon 
(fig.4). 
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Fig.3. Displacement of binding of ~5I-labdled truncated- 
GLP-1 by: B, truncated-GLP-1 (6 x 10 -7 mold) (n = 10); C, 
GLP-I (6 x 10 -7 mol/l) (n = 4); D, glucagon (10 -~ mol/l) (n = 
6); and E, gastric inhibitory p~tide (3 x 10 -7 mol/l) (n = 3) as 
°70 of control (A, no addition of unlabelled peptide). 
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Fig.4. Displacement of binding of 125I-labelled glucagon by: B, 
glucagon (10 -6 tool/l) (n = 4); and C, truncated-GLP-I (6x 
10 -7 mol/1) (n = 4) as 0?o of control (A, no addition of 
unlabelled peptide). 
4. DISCUSSION 
Our results indicate that the rat insulinoma cell 
line RIN 5AH has specific receptors for truncated- 
GLP-1. The non-specific binding found in this 
study is rather high. The identical NSBs found at 
20°C and 4°C, where internalization does not oc- 
cur [8], rule out that the rather high NSB is due to 
internalization. It is more likely that the extensive 
degradation of the labelled peptide during incuba- 
tions, demonstrated by precipitation of labelled 
peptide in 5 %0 trichloroacetic a id, can account for 
the high NSB. Possibly, low molecular mass 
radioactive degradation products may enter the 
cells during the incubations. 
In agreement with our findings, Drucker et al. 
[9] recently described an effect on insulin gene ex- 
pression of this peptide on a similar cell line, RIN 
1046-38. These results are also in agreement with 
the strong insulinotrophic effect of truncated- 
GLP-1 on pig pancreas, earlier reported by our 
laboratory [3] and on rat pancreas reported by 
Mojsov et al. [4]. 
Glucagon (proglucagon 33-61) is known as a 
potent stimulus for insulin release [10], and recep- 
tors for glucagon have been demonstrated on in- 
sulinoma cells from Syrian hamsters [11] and on 
rat insulinoma (RIN-m) cells [12]. We also found 
saturable and specific binding of glucagon to the 
present cell line. However, glucagon did not 
displace the binding of  truncated-GLP-1 and 
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truncated-GLP-1 did not displace the binding of 
glucagon. Therefore, truncated-GLP-1 and 
glucagon have separate receptors. The mean 
binding of 125I-labelled truncated-GLP-1 to RIN 
5AH cells was slightly higher in the presence of 
glucagon than alone (fig.3). This finding was not 
significant. In all four experiments he binding of 
t25I-labelled glucagon in the presence of truncated- 
GLP-1 was higher than the binding of glucagon 
alone (fig.4). We do not have any explanation for 
this finding. The related peptide gastric inhibitory 
peptide, also known as a potent insulin releasing 
peptide, which also possesses specific receptors on 
beta cells [13], was without effect on the binding of 
truncated-GLP-I suggesting that the GIP receptor 
is not responsible for the binding of truncated- 
GLP-1. 
The concentration of truncated-GLP-1 required 
for half-maximum binding was 3 x 10 -9 mol/l. 
This is in agreement with the pronounced effect on 
insulin secretion of this concentration of the pep- 
tide in the isolated perfused porcine pancreas [3]. 
A similar value was found for the interaction of 
glucagon with its receptor. Thus our results pro- 
vide further support for the theory that truncated- 
GLP-1, secreted from the lower small intestine, 
may play a physiological role in the control of in- 
sulin secretion. 
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